Account Login
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Blueprint Medicines Corp (NQ: BPMC )

96.26 USD +1.86 (+1.97%)
Streaming Delayed Price Updated: 10:48 AM EDT, Apr 23, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 42,668
Open 94.88
Bid (Size) 96.26 (1)
Ask (Size) 96.56 (1)
Prev. Close 94.40
Today's Range 93.96 - 96.64
52wk Range 56.00 - 125.61
Shares Outstanding 57,957,641
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Blueprint Medicines to Report First Quarter 2021 Financial Results on Thursday, April 29, 2021
Blueprint Medicines Corporation (NASDAQ: BPMC), today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, April 29, 2021 to report its first quarter 2021... 
From PR Newswire
Blueprint Medicines Data Highlight Clinical Leadership in Systemic Mastocytosis at AACR Annual Meeting 2021
-- 75% confirmed ORR, with all responses ongoing, in PATHFINDER trial of AYVAKIT in advanced SM -- 
From PR Newswire

Performance

YTD
-7.95%
-7.95%
1 Month
-2.63%
-2.63%
3 Month
-3.61%
-3.61%
6 Month
-6.38%
-6.38%
1 Year
+37.22%
+37.22%

More News

Read More
Blueprint Medicines Presents Preclinical Data Highlighting Broad Precision Therapy Research Pipeline at AACR Annual Meeting 2021
From PR Newswire
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From PR Newswire
Blueprint Medicines to Host Virtual Investor Event and Webcast to Review New Data Presented at AACR Annual Meeting on Monday, April 12, 2021
From PR Newswire
Blueprint Medicines to Showcase Scientific Leadership in Precision Oncology and Hematology at AACR Annual Meeting 2021
From PR Newswire
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From PR Newswire
Blueprint Medicines Announces EMA Validation of Type II Variation Marketing Authorization Application for AYVAKYT® (avapritinib) for the Treatment of Advanced Systemic Mastocytosis
From PR Newswire
IMV Appoints Kyle Kuvalanka to Board of Directors
From Business Wire News Releases
Blueprint Medicines Reports Fourth Quarter and Full Year 2020 Financial Results
From PR Newswire
First Week of June 18th Options Trading For Blueprint Medicines (BPMC)
Tags Stocks
From Market News Video
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.